Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Apoptosis in response to microbial infection induces autoreactive TH17 cells.

Campisi L, Barbet G, Ding Y, Esplugues E, Flavell RA, Blander JM.

Nat Immunol. 2016 Sep;17(9):1084-92. doi: 10.1038/ni.3512. Epub 2016 Jul 25.

2.

Bovine herpesvirus 4-based vector delivering a hybrid rat/human HER-2 oncoantigen efficiently protects mice from autochthonous Her-2+ mammary cancer.

Jacca S, Rolih V, Quaglino E, Franceschi V, Tebaldi G, Bolli E, Rosamilia A, Ottonello S, Cavallo F, Donofrio G.

Oncoimmunology. 2015 Aug 31;5(3):e1082705. eCollection 2016 Mar.

3.

Clonal Abundance of Tumor-Specific CD4(+) T Cells Potentiates Efficacy and Alters Susceptibility to Exhaustion.

Malandro N, Budhu S, Kuhn NF, Liu C, Murphy JT, Cortez C, Zhong H, Yang X, Rizzuto G, Altan-Bonnet G, Merghoub T, Wolchok JD.

Immunity. 2016 Jan 19;44(1):179-93. doi: 10.1016/j.immuni.2015.12.018.

4.

How many TCR clonotypes does a body maintain?

Lythe G, Callard RE, Hoare RL, Molina-París C.

J Theor Biol. 2016 Jan 21;389:214-24. doi: 10.1016/j.jtbi.2015.10.016. Epub 2015 Nov 7.

5.

Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy.

Perica K, Bieler JG, Schütz C, Varela JC, Douglass J, Skora A, Chiu YL, Oelke M, Kinzler K, Zhou S, Vogelstein B, Schneck JP.

ACS Nano. 2015 Jul 28;9(7):6861-71. doi: 10.1021/acsnano.5b02829. Epub 2015 Jul 14.

6.

Impaired gp100-Specific CD8(+) T-Cell Responses in the Presence of Myeloid-Derived Suppressor Cells in a Spontaneous Mouse Melanoma Model.

Mairhofer DG, Ortner D, Tripp CH, Schaffenrath S, Fleming V, Heger L, Komenda K, Reider D, Dudziak D, Chen S, Becker JC, Flacher V, Stoitzner P.

J Invest Dermatol. 2015 Nov;135(11):2785-93. doi: 10.1038/jid.2015.241. Epub 2015 Jun 29.

7.

Pathogen-Specific T Cell Polyfunctionality Is a Correlate of T Cell Efficacy and Immune Protection.

Boyd A, Almeida JR, Darrah PA, Sauce D, Seder RA, Appay V, Gorochov G, Larsen M.

PLoS One. 2015 Jun 5;10(6):e0128714. doi: 10.1371/journal.pone.0128714. eCollection 2015. Erratum in: PLoS One. 2015;10(9):e0138395.

8.

Microenvironment of tumor-draining lymph nodes: opportunities for liposome-based targeted therapy.

Chandrasekaran S, King MR.

Int J Mol Sci. 2014 Nov 5;15(11):20209-39. doi: 10.3390/ijms151120209. Review.

9.

Identification of the genomic insertion site of Pmel-1 TCR α and β transgenes by next-generation sequencing.

Ji Y, Abrams N, Zhu W, Salinas E, Yu Z, Palmer DC, Jailwala P, Franco Z, Roychoudhuri R, Stahlberg E, Gattinoni L, Restifo NP.

PLoS One. 2014 May 14;9(5):e96650. doi: 10.1371/journal.pone.0096650. eCollection 2014.

10.

Shaping the repertoire of tumor-infiltrating effector and regulatory T cells.

Savage PA, Leventhal DS, Malchow S.

Immunol Rev. 2014 May;259(1):245-58. doi: 10.1111/imr.12166. Review.

11.

Direct T cell activation via CD40 ligand generates high avidity CD8+ T cells capable of breaking immunological tolerance for the control of tumors.

Soong RS, Song L, Trieu J, Lee SY, He L, Tsai YC, Wu TC, Hung CF.

PLoS One. 2014 Mar 24;9(3):e93162. doi: 10.1371/journal.pone.0093162. eCollection 2014.

12.

Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent antitumor activity.

Dougan SK, Dougan M, Kim J, Turner JA, Ogata S, Cho HI, Jaenisch R, Celis E, Ploegh HL.

Cancer Immunol Res. 2013 Aug;1(2):99-111. doi: 10.1158/2326-6066.CIR-13-0047.

13.

Chimeric DNA Vaccines against ErbB2+ Carcinomas: From Mice to Humans.

Quaglino E, Riccardo F, Macagno M, Bandini S, Cojoca R, Ercole E, Amici A, Cavallo F.

Cancers (Basel). 2011 Aug 10;3(3):3225-41. doi: 10.3390/cancers3033225.

14.

Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice.

Sanchez-Perez LA, Choi BD, Archer GE, Cui X, Flores C, Johnson LA, Schmittling RJ, Snyder D, Herndon JE 2nd, Bigner DD, Mitchell DA, Sampson JH.

PLoS One. 2013;8(3):e59082. doi: 10.1371/journal.pone.0059082. Epub 2013 Mar 18.

15.

T cell responses to antigen: hasty proposals resolved through long engagements.

Tkach K, Altan-Bonnet G.

Curr Opin Immunol. 2013 Feb;25(1):120-5. doi: 10.1016/j.coi.2012.12.001. Epub 2012 Dec 28. Review.

16.
17.

Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype.

Hirschhorn-Cymerman D, Budhu S, Kitano S, Liu C, Zhao F, Zhong H, Lesokhin AM, Avogadri-Connors F, Yuan J, Li Y, Houghton AN, Merghoub T, Wolchok JD.

J Exp Med. 2012 Oct 22;209(11):2113-26. doi: 10.1084/jem.20120532. Epub 2012 Sep 24.

18.

Evaluating cellular polyfunctionality with a novel polyfunctionality index.

Larsen M, Sauce D, Arnaud L, Fastenackels S, Appay V, Gorochov G.

PLoS One. 2012;7(7):e42403. doi: 10.1371/journal.pone.0042403. Epub 2012 Jul 30.

19.

Interrogating the repertoire: broadening the scope of peptide-MHC multimer analysis.

Davis MM, Altman JD, Newell EW.

Nat Rev Immunol. 2011 Jul 15;11(8):551-8. doi: 10.1038/nri3020. Review.

20.

Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.

Klebanoff CA, Gattinoni L, Palmer DC, Muranski P, Ji Y, Hinrichs CS, Borman ZA, Kerkar SP, Scott CD, Finkelstein SE, Rosenberg SA, Restifo NP.

Clin Cancer Res. 2011 Aug 15;17(16):5343-52. doi: 10.1158/1078-0432.CCR-11-0503. Epub 2011 Jul 7.

Supplemental Content

Support Center